{"organizations": [], "uuid": "b3a45e624b4c51a4def0a1e601660bebd52d4cb6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180427.html", "section_title": "Archive News &amp; Video for Friday, 27 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-acelrx-receives-positive-chmp-opin/brief-acelrx-receives-positive-chmp-opinion-for-dzuveo-for-management-of-acute-moderate-to-severe-pain-in-medically-monitored-settings-idUSFWN1S40Z3", "country": "US", "domain_rank": 408, "title": "BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.228, "site_type": "news", "published": "2018-04-27T19:22:00.000+03:00", "replies_count": 0, "uuid": "b3a45e624b4c51a4def0a1e601660bebd52d4cb6"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-acelrx-receives-positive-chmp-opin/brief-acelrx-receives-positive-chmp-opinion-for-dzuveo-for-management-of-acute-moderate-to-severe-pain-in-medically-monitored-settings-idUSFWN1S40Z3", "ord_in_thread": 0, "title": "BRIEF-AcelRx Receives Positive CHMP Opinion For Dzuveo For Management Of Acute Moderate To Severe Pain In Medically Monitored Settings", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "acelrx pharmaceuticals inc", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 27 (Reuters) - AcelRx Pharmaceuticals Inc:\n* ACELRX RECEIVES POSITIVE CHMP OPINION FOR DZUVEOâ„¢ FOR MANAGEMENT OF ACUTE MODERATE TO SEVERE PAIN IN MEDICALLY MONITORED SETTINGS\n* ACELRX PHARMACEUTICALS INC - RESUBMISSION OF NEW DRUG APPLICATION FOR DSUVIA (KNOWN AS DZUVEO IN EUROPE) TO FDA IN U.S. IS PLANNED FOR Q2 Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-27T19:22:00.000+03:00", "crawled": "2018-04-28T12:59:13.002+03:00", "highlightTitle": ""}